Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Basic Genomic Research To Biomedical Research To Translational Medicine To Medical Applications | 17042
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1770

Journal of Biotechnology & Biomaterials received 1770 citations as per Google Scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Basic genomic research to biomedical research to translational medicine to medical applications

5th World Congress on Biotechnology

Manuel P?rez Alonso

Keynote: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.026

It is widely recognized that there is a gap between basic biomedical research and medical applications. This gap derives from the need of a process of technology transfer to private companies that will eventually exploit those applications. Such process is complex and involves a number of players, i.e., scientists, technology transfer officers, legal advisors and business people so it can take from months to years. Also, there is an increasing concern about the fact that many scientists concentrate most of their efforts in publishing papers in order to be more competitive, so that in the next grant application their research group will receive a new grant. All these facts bring the obvious result, i.e., biomedical research is normally not translated into the practical applications that should bring the expected benefit for patients, despite the large investment that many countries make in basic research. A clear example of this problem is the small number of new drugs that have been developed in the last decade, despite the promise that, after sequencing the first draft of the human genome, a wave of new therapies would be developed. Similarly, more than a decade after the first draft of the human genome was obtained thousands of human genetic diseases still do not have a known molecular basis. In this talk the author will present my personal experience in translating basic knowledge in genetics and genomics into medical applications through entrepreneurship in science, mainly in two fields: Medical Genetics and Drug Discovery. Also, he will present the Spanish Association of Entrepreneurs in Science and the need to create the European Association of Entrepreneurs in Science.
Manuel P?rez Alonso has a degree in Biology and PhD in Molecular Genetics. He is Genetics Professor at the University of Valencia. He participated in five international genome sequencing consortia and (as PI) in a number of basic research projects. He is promoter and founding partner in four biomedical companies: Valentia BioPharma, The Institute of Genomic Medicine, GenAGen and Genera Biotech all of them located at the University of Valencia Science Park. His research is now focused in the development of genomics tools for genetic testing. He also contributes to biopharmaceutical research through the study of the pathways leading to rare genetic disease. He is President of the Valencia BioRegion (BIOVAL) and President of the Spanish Association of Entrepreneurs in Science.